Fidelity Advisor Biotechnology A holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Fidelity Advisor Biotechnology Fund - Class A FBTAX
- NAV / 1-Day Return 46.17 / +1.65 %
- Total Assets 2.2B
-
Adj. Expense Ratio
0.960%
- Expense Ratio 0.960%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.98%
- Turnover 51%
USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 4:51 AM GMT+0
Morningstar’s Analysis FBTAX
Will FBTAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 14.76 | 281M | Healthcare |
Gilead Sciences Inc | 6.57 | 125M | Healthcare |
Alnylam Pharmaceuticals Inc | 5.39 | 103M | Healthcare |
Dianthus Therapeutics Inc | 3.57 | 68M | Healthcare |
Insmed Inc | 3.47 | 66M | Healthcare |
argenx SE ADR | 3.39 | 65M | Healthcare |
Cogent Biosciences Inc | 3.37 | 64M | Healthcare |
Spyre Therapeutics Inc | 3.31 | 63M | Healthcare |
Ascendis Pharma AS | 3.17 | 60M | Healthcare |
Biogen Inc | 3.03 | 58M | Healthcare |
United States